New data from phase IIIb study reinforces safety profile of Roche ’s Hemlibra in people with haemophilia A

Roche today announced results from the second interim analysis of the phase IIIb STASEY study, which reinforce the safety profile of Hemlibra ® (emicizumab) characterised in the phase III HAVEN clinical programme.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news